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Abstract (249/250 words) 
Polypharmacy is widespread and associated with medication-related harms, including 
adverse drug reactions, medication errors and poor treatment adherence. General 
practitioners and pharmacists cite limited time and training to perform effective medication 
reviews for patients with complex polypharmacy, yet no specialist referral mechanism 
exists. Aims. To develop a structured framework for specialist review of primary care 
patients with complex polypharmacy. Methods. We developed the Clinical Pharmacology 
Structured Review (CPSR) and Stopping By Indication Tool (SBIT). We tested these in an age-
sex stratified sample of 100 people with polypharmacy aged 65-84 years from the Clinical 
Practice Research Datalink, an anonymised primary care database. Simulated medication 
reviews based on electronic records using the CPSR and SBIT were performed. We 
recommended medication changes or review to optimise treatment benefits, reduce risk of 
harm or reduce treatment burden. Results. Recommendations were made for all patients, 
for almost half (4.8±2.4) of existing medicines (9.8±3.1), most commonly stopping a drug 
(1.7±1.3/patient) or reviewing with patient (1.4±1.2/patient). At least one new medicine 
(0.7±0.9) was recommended for 51% patients. Recommendations predominantly aimed to 
reduce harm (44%). There was no relationship between number of recommendations made 
and time since last primary care medication review. We identified a core set of clinical 
information and investigations (polypharmacy workup) that could inform a standard screen 
prior to specialist review. Conclusions. The CPSA, SBIT and polypharmacy workup could 
form the basis of a specialist review for patients with complex polypharmacy. Further 
research is needed to test this approach in patients in general practice.  
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What is already known about this subject: 
 Polypharmacy is common and is associated with multiple adverse health outcomes 
 Medication reviews are conducted in primary care by general practitioners and 
clinical pharmacists, but can be challenging in patients with complex polypharmacy 
 There is no established mechanism for referral of patients with complex 
polypharmacy for specialist review, in contrast to other long term conditions 
What this study adds: 
 We have developed the Clinical Pharmacology Structured Review (CPSR), Stopping 
By Indication Tool (SBIT) and polypharmacy workup as a structured framework for 
specialist review of complex polypharmacy 
 Analysis of longitudinal primary care data indicates this framework could be a useful 
addition to the existing medication review process 
 The CPSR, SBIT and polypharmacy workup could have particular utility for primary 
care patients with complex polypharmacy 
Keywords 
clinical pharmacology, primary care, prescribing, drug utilization, quality use of medicines, 
medication review, frailty, long term conditions  
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Introduction 
Polypharmacy, the simultaneous use of multiple medicines by one person, is very common, 
with 21% of UK adults aged 20 and older dispensed ≥5 medicines and 6% dispensed ≥10 
medicines in the previous 84 days [1]. Polypharmacy is increasingly prevalent; the number 
of prescriptions in England doubled from 10 to 20 per person between 1997 and 2016 [2]. 
Whilst polypharmacy is associated with frail older adults [1,3], it can affect people of all ages 
[4]. Polypharmacy is often appropriate and of benefit to patients with multiple 
comorbidities. However, the more medicines a person takes, the more likely they are to 
experience harm. For every additional prescription, the risk of an adverse drug reaction 
increases by 13% [5], medication error by 16% [6] and poor adherence by 14% [7]. Patients 
with polypharmacy are more likely to be prescribed high risk medicines [8, 9], yet changes in 
pharmacokinetics and pharmacodynamics in this multi-morbid population may result in 
reduced effectiveness of medication and increased risk of harm [10,11]. Furthermore, such 
patients are less likely to be prescribed prophylactic medicines [8], for example, to reduce 
cardiovascular risk [12,13] and the efficacy of therapy is more likely to be reduced by drug-
drug interactions [14-16]. 
Medicines optimisation is the process of ensuring that medicine use is safe and effective and 
that patients get the best possible outcomes from their medicines [17]. Medication reviews 
in primary care, predominantly carried out by general practitioners and clinical pharmacists, 
are used to optimise the impact of medicines, minimise the number of medication-related 
problems and reduce waste [18]. Medication reviews for the most complex patients with 
polypharmacy present a number of challenges. Patients with multimorbidity are typically 
excluded from randomised controlled trials [19,20] and so guidelines for the treatment of 
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single diseases may have limited applicability to these patients [21-23]. Understandably, GPs 
cite a lack of time to optimise medicines and a reluctance to alter the status quo in such 
patients [24] and clinical pharmacists have less confidence with prescribing for complex 
multimorbidity [25]. Deprescribing, the process of ensuring the safe and effective 
withdrawal of inappropriate medicines [26] is widely recommended for inappropriate 
polypharmacy, but evidence-based guidelines to support this are limited [27-29]. It can 
therefore be difficult for clinicians to decide whether continuing or stopping a medicine 
would be in the best interest of their patient. In addition, the fragmented multi-speciality 
configuration of modern healthcare and a lack of time and resources are substantial barriers 
to effective deprescribing [30-32].  
There is currently no established mechanism of onward referral and advice to support the 
care of primary care patients with complex polypharmacy in the UK. A dedicated service, 
provided by medicines specialists such as clinical pharmacologists (doctors with particular 
expertise in the use of medicines), senior pharmacists, experienced GPs or geriatricians, 
could be a useful addition to support complex patients. The aim of our study was to develop 
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are provided by patients and collected by the NHS as part of their care and support. The 
interpretation and conclusions contained in this report are those of the authors alone. The 
protocol number (18_023) was approved by the Independent Scientific Advisory Committee 
evaluation of joint protocols of research involving CPRD data in March 2018. 
Clinical Pharmacology Structured Review 
The Clinical Pharmacology Structured Review (CPSR), was developed as a body systems 
based approach for performing complex medication reviews (Supplementary table 1 shows 
an example review for one patient). Diagnoses are sorted by body system (e.g. 
cardiovascular, respiratory) as defined by British National Formulary (BNF) chapters [34]. 
Clinical measurements and test results required to assess disease control are aligned with 
diagnoses. Medicines are sorted by system/BNF chapter rather than diagnosis, due to 
overlapping indications and multiple medicines for individual diagnoses. This structured 
alignment of body systems and medication allows better recognition of over- and under-
treatment than the customary chronological diagnosis and alphabetical medication listings. 
Participants 
The CPSR was developed using data from patients on the Clinical Practice Research Datalink 
(CPRD), an anonymised primary care database, which comprises 11.3 million historical 
records from patients in 674 practices in the UK as of 2015 [35]. Twenty-five of these 
practices, which were still contributing data throughout 2016, were selected at random. 
From each, one male and one female patient aged 65-74 and one male and one female 
patient aged 75-84 were randomly selected, all of whom had repeat prescriptions for 10 or 
more unique medication classes in 2016 and were still registered at the end of the year.  
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Medicines were grouped according to the third level (paragraph) of the British National 
Formulary hierarchical classification of medication as per our previous research [36]. 
Medication classes from BNF chapters 1-13 were included [34]. Non-medication entries (e.g. 
medical devices) or other chapters (e.g. vaccines, anaesthesia and emergency treatment for 
poisoning) were excluded. 
Patient information available to the researchers included historical diagnoses and every 
prescription issued while registered at their current practice, including the date of 
prescription, medicine name, strength and number (e.g. of tablets) supplied. Pathology 
results, symptoms, administrative data and some basic examination records were also 
available, including pulse rate, blood pressure and body mass index. Information up to and 
including 31st December 2016 was included as this was the date set for the simulated review 
(see protocol). 
Protocol  
Clinical Pharmacology Structured Review 
Demographic data, including anonymised patient identification (ID) number, sex, year of 
birth and frailty, were collected for each patient, including the date of the last primary care 
medication review where applicable. Frailty was assessed using the electronic frailty index 
(eFI) [37], a validated measure of frailty created by using an equally weighted sum of 36 
routinely recorded deficits, such as heart failure, osteoporosis, and memory and cognitive 
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0-4 deficits = score 0 to 0.12 represents patients without frailty; 
5-8 deficits = score >0.12 to 0.24 represents patients with mild frailty; 
9-12 deficits = score >0.24 to 0.36 represents patients with moderate frailty; and 
13+ deficits = score >0.36 represents patients with severe frailty. 
Simulated medication reviews, using the CPSR were conducted as if they were occurring on 
31st December 2016, using all clinical data available up to that date. Medicines reviewed 
were those prescribed as repeat prescriptions between October to December 2016, i.e. 
within three months preceding the review. Each patient was discussed by a team of clinical 
pharmacologists comprising a consultant and three trainee doctors, with additional input 
from primary care and pharmacy for some cases. Each prescription was discussed and 
reviewed in context of the patient’s clinical and investigation information and the best 
available evidence. Evidence was used in order of hierarchy, with National Institute for 
Health and Care Excellence (NICE) guidelines; other national or international guidelines; 
meta-analyses and systematic reviews; and single randomised control trials in decreasing 
order of importance. 
A final recommendation (Table 1) and purpose of the recommendation were recorded.  
Purposes were defined as follows: 
 treatment appropriate - no change is required 
 optimise benefit - to improve disease or symptom control 
 reduce harm - to reduce actual or potential harms of treatment 
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 reduce treatment burden - where a change is unlikely to optimise benefit or reduce 
harm, but where stopping or reducing treatment will reduce the burden on the 
patient or healthcare system 
Polypharmacy workup 
Clinical measurements and investigation results were used to assess disease control and the 
appropriateness of prescriptions during medication review. The necessity of each test was 
considered on an individual patient basis. A test result was deemed essential where a 
recommendation could not be made without it and useful if it was helpful but not essential 
to the recommendation.  
Stopping By Indication Tool 
Given that there is limited evidence to support deprescribing in patients with polypharmacy 
and complex co-morbidities, the Stopping By Indication Tool (SBIT) was developed to guide 
decision making. The initial prescriptions of all patients were categorised by treatment goal 
into four main groups: symptom control; prevention/prognosis; disease control; and 
prescribing cascade, using information available regarding each patient’s prescriptions and 
diagnoses. The treatment goal categories were defined as follows: 
 Symptom control – medicine controls symptoms through mechanisms not specific to 
the disease process and does not affect prognosis (e.g. opioids for pain) 
 Prevention/prognosis – medicine reduces the risk of onset or progression of a 
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 Disease control – medicine targets disease process to control symptoms but does 
not affect prognosis (e.g. furosemide for heart failure, tamsulosin for benign 
prostatic hypertrophy) 
 Prescribing cascade – medicine prescribed to mitigate the actual or potential harm of 
another medicine (e.g. proton pump inhibitors as gastroprotection for antiplatelet 
therapy) 
Where medicines had more than one indication, the most important indication was 
allocated on a case-by-case basis, based on the aspect of treatment that seemed most 
important for the patient’s care. 
Supplementary table 2 shows the decision aid used for the SBIT to categorise repeat 
prescriptions in our dataset.  This decision aid was developed using an iterative process and 
contains diagnoses present in the dataset.  
Analysis 
Continuous data were described using mean ± standard deviation (SD) where normally 
distributed, and median [interquartile range] where not normally distributed. Pearson 
correlations were used for continuous data and Spearman rank correlations for ordinal data. 
Mann-Whitney U tests were used to compare independent non-parametric variables and 
chi-squared tests were used to compare categorical variables. Statistical analysis was 
performed in SPSS (version 25).  
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Results 
One hundred patients were selected, age 74±6 years, 50% female. Patients had 7.5±2.8 long 
term conditions and, on average, were moderately frail, with an electronic frailty index (eFI) 
score of 0.28±0.1. In total, 982 existing repeat prescriptions were reviewed, with 9.8±3.1 
(range 3-21) per patient. A substantial majority (956; 97%) of prescriptions were from the 
top 100 most commonly prescribed drug classes in the UK [38]. A primary care medication 
review was documented in the last six months for 33% and in the last year for 70% of 
patients. Time since last medication review was 231 [107-411] days. There were no 
significant differences between patients who did or did not have a medication review in the 
last 6 or 12 months in terms of age, eFI score or number of initial prescriptions (Table 2). 
Clinical Pharmacology Structured Review 
In all patients, the CPSR identified at least one potential change in medication or need for 
review with further information; in total, leading to 5.5±2.7 (range 1-15) recommendations 
per patient (Table 3). We identified recommendations for almost half (4.8±2.4) of existing 
medicines (9.8±3.1) and recommended starting at least one new medicine for 51% patients, 
with an average of 0.7±0.9 new medicines per patient. 
The most common recommendations were to stop medicines (1.7±1.3 per patient) and 
review a medicine with the patient (1.4±1.2 per patient). In terms of the purpose of the 
recommendations, 2.5±1.9 (44%) aimed to reduce harm, 1.6 ±1.6 (28%) aimed to optimise 
benefit and 1.6±1.4 (28%) aimed to reduce treatment burden.  
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Relationship between patient and medication factors and recommendations 
There was no significant correlation between the number of recommendations made and 
patient factors (age (r=-0.06, P=0.53) or electronic frailty index (eFI) score (r=0.10, P=0.31)).  
The number of repeat prescriptions was positively correlated with the number of 
recommendations made (r=0.55, P<0.001), but there was no significant correlation between 
the number of repeat prescriptions and the proportion of medicines receiving 
recommendations (r=-0.02, P=0.84).  
There was no significant correlation between the time since the last primary care 
medication review and the number of recommendations made (r=-0.07, P=0.49). There 
were no significant differences in the number of recommendations between patients who 
did or did not have a medication review in the last 6 months (review 6 [4-8] 
recommendations; no review 5 [3-6] recommendations, P=0.322) or 12 months (review 5 [4-
7] recommendations; no review, 5 [3-6], P=0.90). 
Polypharmacy workup 
Figure 1 shows measurements and investigations required for assessment of diagnosis 
and/or disease control that were considered either essential or useful in decision making at 
medication review. Some measurements, such as renal function, blood pressure and blood 
lipids were required for most patients (≥90%), whereas others, such as erythrocyte 
sedimentation rate (ESR), were needed less often. Serum magnesium was deemed useful 
mostly in the case of proton pump inhibitor use, due to risk of hypomagnesaemia. 
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Stopping By Indication Tool (SBIT) 
Supplementary table 3 shows medication classes reviewed for the 100 patients, categorised 
by their indication. For example, a proton pump inhibitor prescribed for a patient with 
dyspepsia was categorised as being for symptom control; in the presence of peptic ulcer 
disease or previous gastrointestinal (GI) bleeding, it was categorised as being for disease 
control, and where co-administered with drugs with gastrointestinal adverse effects (such as 
non-steroidal anti-inflammatories), where there was no GI diagnosis, it was categorised as 
being part of a prescribing cascade. Out of 982 repeat prescriptions reviewed for 100 
patients, 420 (43%) of prescriptions were for disease control, 230 (23%) for symptom 
control, 296 (30%) for prevention/prognosis and 36 (4%) for prescribing cascade. Table 4 
compares recommendations by indication. Recommendations to stop medication or reduce 
dose were made for 50% (18/36) of prescribing cascade medicines, 30% (68/230) of 
medicines for symptom control, 20% (83/420) of medicines for disease control and 16% 
(46/296) of medicines for prevention/prognosis. Medicines for prevention/prognosis were 
most likely to have no change recommended. 
 
Discussion 
Main study findings 
We have developed a framework comprising the Clinical Pharmacology Structured Review 
(CPSR), polypharmacy workup and Stopping By Indication Tool (SBIT) for specialist review of 
complex polypharmacy. Using this structured approach to perform medication reviews, we 
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identified many potential medication changes, irrespective of recent medication review in 
primary care. This indicates that a specialist assessment could add value for primary care 
patients with complex polypharmacy. Detailed analysis of recommendations identified 
clinical data that was commonly required to support decision making, and could be used to 
inform a standard polypharmacy workup for instigation prior to structured medication 
review. Recommendations to stop medicines or reduce doses were more common for 
medicines used for symptom control and those prescribed to mitigate against the effects of 
other medicines (prescribing cascade), than for medicines used for prevention/prognosis or 
disease control. The SBIT could potentially support deprescribing in primary care, where 
evidence based guidelines are lacking. 
Study strengths and weaknesses 
The CPSR, polypharmacy workup and SBIT were developed by clinical pharmacologists in 
collaboration with academic primary care colleagues (who are practising general 
practitioners), population health specialists and epidemiologists. It describes an approach 
that could be taken for the review of patients with complex polypharmacy in a specialist 
service. It was developed using primary care medical records of real UK patients from CPRD, 
a database representative of UK patients in terms of age, sex and ethnicity [35,39]. It is 
therefore likely to be applicable to patients across the UK.  Medical records were 
longitudinal, allowing for a comprehensive assessment of patients’ overall health and 
treatment.  This meant that medication reviews could take into account previous 
therapeutic strategies and make recommendations that were more likely to be suitable for 
the patient.   
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A patient-centred approach is important in medicines optimisation [40] and a key limitation 
of this project is the lack of patient involvement. Whilst medication reviews in primary care 
are also often undertaken without the patient present [41], there is limited evidence that 
participation of patients increases the identification of medication related problems [42].  
Issues may have come to light if we had been able to speak to patients in our study, which 
could have altered our prescribing decision making. Additional benefits of medication 
reviews, including improving patients’ knowledge, satisfaction and adherence to therapy, 
are also important factors to address. By not speaking to the prescribing general 
practitioners for the selected patients it is also difficult to estimate the proportion of our 
recommendations that would be acted upon in primary care. Despite receiving 
recommendations to change medicines, additional barriers of feasibility (e.g. a lack of time 
and resources, patient characteristics and preferences) and inertia (e.g. if stopping a 
medicine is considered futile) [30] may limit the number of recommendations implemented. 
Another limitation of this analysis was the lack of secondary care data.  Most repeat 
prescriptions initiated in secondary care are continued in primary care by general 
practitioners, either directly or under shared care agreements, and these would be picked 
up by CPRD. However, rarer, secondary care only prescribing (e.g. biologics, chemotherapy 
etc.) are not recorded routinely in primary care and would be missing or incomplete in 
CPRD.  Indications for some medicines were also not always clear, possibly because 
secondary care diagnoses were not always documented in CPRD. In real patient 
consultations, incomplete medical records would negatively impact the utility of the CPSR.  
In such cases it might only be possible to make recommendations on a limited number of 
medicines and plan to repeat the process once more information had been gathered.  
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However, this would also be the case in any other medical consultation.  When conducting 
real medication reviews using the CPSR, the clinician would need access to primary care 
records, which would include clinic letters and discharge summaries containing the majority 
of salient secondary care data.  Further information could also be obtained from the patient. 
Analysis of the relationship between previous medication review and recommendations 
made as a result of the CPSR and SBIT framework were limited by a lack of information of 
the type of medication reviews documented in our data. There are many different types of 
medication review, differing in terms of the purpose (holistic or focussed on a specific 
condition or medication), the level of access to patient records, the healthcare professional 
undertaking the review and whether or not the patient was present for the review [43]. 
These potential confounding factors may have influenced our findings, because the type of 
review may have impacted on the appropriateness of medication and thus the number of 
recommendations made during this study. 
Comparison with other studies 
There are a number of existing tools for medication review, and these can be broadly 
categorised as explicit or implicit. Explicit tools, such as the STOPP/START criteria [44] and 
Beers criteria [45] provide specific, algorithm-based guidance about medication. Explicit 
tools do not rely on users to have a detailed knowledge of medicines and thus are useful 
even for relatively inexperienced healthcare professionals. Explicit tools benefit from being 
widely used and generalisable to the majority of patients.  However, this rules-based 
approach means such tools are less adaptable to individual patients’ preferences, lifestyles 
and patterns of comorbidities. 
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Implicit tools, such as the Medication Appropriateness Index [46] provide a framework 
whereby clinical judgements of the appropriateness of medication can be made. They 
require healthcare professionals to have the knowledge, experience and time to make 
judgements, but allow for a more flexible and thus patient-centred approach. Implicit tools, 
whilst time consuming, offer the potential for specialist review for complex patients.  A 
recent study of an implicit tool for deprescribing multiple medicines (‘poly-de-prescribing’) 
demonstrated significant improvement, or less deterioration, in general satisfaction, 
functional, mental and cognitive status, sleep quality, appetite and sphincter control in 
patients with extensive polypharmacy where poly-de-prescribing was achieved [47].  Whilst 
this was not a randomised controlled trial, it indicates the potential for implicit tools to 
benefit a subset of patients with extensive polypharmacy.   
The CPSR and SBIT framework is an implicit tool to support specialist review of patients with 
complex polypharmacy. By taking a body systems focussed approach to medication review, 
it allows recommendations to be made to optimise medicines for patients that can 
supplement and support the primary care medication review process. Increases in 
multimorbidity and frailty, complexity of medication regimens, patient expectations and 
pressure in the healthcare system make the medication review process ever more complex. 
Specialist input could support primary care networks in managing the most complex 
patients. 
Components of the CPSR and SBIT could be used more widely to support medication 
reviews. To our knowledge, this is the first time that the clinical measurements required to 
support polypharmacy review have been described. We found, for example, that renal 
function was essential or useful for 99% of reviews, but was not available in 10% of cases.  
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The majority of these measurements are routinely made in primary care but absence of 
these data could impact decision making.  Consistent availability of results would ensure 
that healthcare professionals have sufficient information to make informed 
recommendations regarding medicines optimisation. These investigations could be used to 
develop a ‘polypharmacy workup’ to be initiated prior to referral to increase the efficiency 
of the medication review process for the most complex patients. 
Deprescribing can be particularly difficult, with barriers including lack of evidence-based 
guidelines. The SBIT can be used to support discussions around deprescribing by classifying 
medicines by their general clinical purpose and considering the consequences of stopping 
(Table 5). For example, where a medicine is prescribed for symptom control, the risk of 
stopping that medicine is a return or worsening of symptoms. Therefore a treatment 
holiday, or changing the administration from ‘regular’ to ‘as required’ may be an acceptable 
first step for many patients.  For example, in a meta-analysis of studies where the dosing 
regimen for proton pump inhibitors was changed from ‘regular’ to ‘as required’, 84% of 
patients reported adequate symptom relief, compared to 91% of those with no change in 
treatment, indicating that the majority of patients tolerated the change and could step 
down treatment [48]. The SBIT can facilitate discussion between the clinician and patient 
about the potential consequences of reducing or stopping the medicine in order to make a 
personalised deprescribing plan.  
Implications for future practice and research 
The CPSR will need to be validated in clinical practice to establish its value in medicines 
optimisation before its widespread use can be recommended.  It will be of particular 
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importance to assess its use in both face-to-face patient consultations and in team meetings 
where multidisciplinary healthcare professionals discuss patient care. 
The 2019 NHS long term plan [49] sets out a strategy to develop primary care networks of 
local GP practices and to integrate primary and specialist care, through new integrated care 
systems.  This strategy, along with the commitment of over £100 million to support an extra 
1,500 clinical pharmacists by 2020 [50], will mean that clinical pharmacists will play a 
greater role in patient care, for example through pharmacist-led medication reviews. This 
may represent an ideal opportunity to test the CPSR in practice, on those patients with the 
most complex polypharmacy, where initial attempts at medicines optimisation have not 
been successful. A multi-professional specialist service [51] of clinical pharmacologists 
(doctors with particular expertise in the use of medicines), senior pharmacists, experienced 
GPs or geriatricians could use the CPSR to perform medication reviews and support GPs and 
clinical pharmacists in primary care. 
Conclusions 
We have developed the Clinical Pharmacology Structured Review, Stopping By Indication 
Tool and polypharmacy workup in order to provide a framework for specialist medication 
reviews for patients with complex polypharmacy. These tools could be incorporated into an 
integrated specialist service to support the care of patients with complex polypharmacy 
where existing medicines optimisation has not been successful. Validation of these tools in 
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Table 1. Categories of recommendations for medicines changes following review using the 
Clinical Pharmacology Structured Review 
Recommendation categories  
Drug changes: 
a) Stop medicine 
b) Start medicine 
c) Reduce dose 
d) Increase dose 
Review with further information: 
a) Review indication 
Where there is no documented indication, but stopping is potentially harmful 
b) Review with patient 
Where further information from the patient, such as symptom control, is 
required 
c) Review with results 
Where prescription review is dependent on monitoring or investigation results 
d) Review with specialist 
Where further information or advice is required from a specialist, or medication 
changes should be made by a specialist only 
a) Planning future treatment 
Where no changes are recommended at present, but an important 




Table 2. Demographics of patients who did or did not have a medication review in the 
previous 6 or 12 months 
 Last medication review 









Age (years) 74±5.6 74±5.7 0.95 75±5.6 73±5.6 0.12 
Gender 
n(%) male 
18 (55%) 32 (48%) 0.52 34 (49%) 16 (53%) 0.66 












10.0±3.4 9.7±2.9 0.73 9.9±3.0 9.5±3.3 0.54 
eFI, electronic frailty index  
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Table 4. Recommendations for reviewed medicines by indication 







 Number % Number % Number % Number % Number % 
No change 106 46% 193 65% 188 45% 13 36% 500 51% 
Stop or reduce dose 68 30% 46 16% 83 20% 18 50% 215 22% 
Increase dose 1 0% 15 5% 7 2% 0 0% 23 2% 
Review with more 
information 
55 24% 42 14% 142 34% 5 14% 244 25% 
Total 230 100% 296 100% 420 100% 36 100% 982 100% 
  





at least one 
recommendation 
(%) 
Existing medicines reviewed: 9.8±3.0 100% 
 Medication changes 2.4±1.4 93% 
 Review with further information 2.4±1.9 88% 
 No change 5.0±2.5 100% 
New medicines to start 0.7±0.9 51% 
Total recommendations (change, review or start) 5.5±2.7 100% 
Summary of recommendations to change existing medicines:  
 Stop medicine 1.7±1.3 80% 
 Reduce dose 0.5±0.7 34% 
 Increase dose 0.2±0.5 20% 
Summary of recommendations to review existing medicines: 
 Review indication 0.3±0.8 18% 
 Review with patient 1.4±1.2 72% 
 Review with results 0.2±0.5 20% 
 Review with specialist 0.4±0.9 23% 
 Planning future treatment 0.1±0.2 5% 
Reasons for existing and new medication recommendations: 
 Optimise benefit 1.6±1.6 77% 
 Reduce harm 2.5±1.9 85% 
 Reduce treatment burden 1.6±1.4 77% 
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Table 5. Stopping By Indication Tool (SBIT) to facilitate deprescribing 
Indication Risk of stopping Approach to deprescribing 
Symptom control Symptom flare Change from regular to as required 
Treatment holiday 
Disease control Disease exacerbation Stop if burden > benefit 
Prevention/prognosis Increased risk of disease event Stop if burden > risk, consider time 
to event for patients with limited 
prognosis 
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Figure 1. Clinical measurements and investigation results considered essential (black bars) 
and useful (grey bars) for making prescribing decisions 
 
Abbreviations: BMI, body mass index; BNP, B-type natriuretic peptide; CRP, c-reactive 
protein; ESR, erythrocyte sedimentation rate; FEV-1, forced expiratory volume in 1 s; HbA1c, 
haemoglobin A1c; HDL, high-density lipoprotein; INR, international normalised ratio; LDL, 
low-density lipoprotein; OGD, oesophagogastroduodenoscopy; RAST, radioallergosorbent 
test; TSH, thyroid stimulating hormone 
